Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...
The European Medicines Agency’s CHMP regulatory committee gave a positive opinion to add a self-administration option for asthma injection Fasenra (benralizumab), based on a new delivery method ...
It does not necessarily reflect the view of The Herald. I recently had the pleasure of visiting Mandara Spa at the Park Plaza Westminster, and my Thursday evening experience was nothing short of ...
They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback